|
|
SABPA Newsletter (Jan. 2009)
| |
 |
|
 |
| Date: |
2009-02-04 |
| Type: |
Newsletter |
| Organizer: |
SABPA |
| Location: |
San Diego |
| Source: |
SABPA |
|
|
|
|
1. SABPA 2nd Entrepreneur Symposium (02/21/09)
2. SABPA New Year Party (01/24/09)
3. SABPA 2008 Awards
4. SABPA7th Science & Technology Forum (San Diego Chapter, 03/21/09)
5. SABPA 4th Biomedical Forum (OC/LA Chapter, 03/28/09)
6. Genengnews Report on 4th SABPA Pacific Forum (11/08/08)
7. Community Events
8. Job Openings
1. 2nd SABPA Entrepreneur Symposium (02/21/09)
When: 5:00 pm to 7:30 pm, Saturday, Feb. 21, 2009
Where: The Institute of Americas, UCSD
Lecture title: How to start a biotech company?
Speaker: Dr. N. Darius Sankey, Partner at Zone Venture Capital
Schedule:
5:00 to 5:30 pm: Reception and Networking
5:30 to 5:40 pm: Welcome and Announcement
5:40 to 6:40 pm: Presentation
6:40 to 7:30 pm: Networking
About speaker:
Dr. N. Darius Sankey is a Managing Director at Zone Ventures, a seed to early stage venture capital firm based in Los Angeles. Dr. Sankey has led the Zone Ventures technology assessment efforts and overseen its portfolio investments for over eight years, serving as a board member for several companies including Siimpel Corporation, Lumexis, Inc. and Microfabrica and Neven Vision (Acquired by Google). He has led several transactions in the micro electronics, wireless telecommunications, media & entertainment, and business & consumer software sectors. Dr. Sankey has a strong interest in strategizing market applications for basic science research on the university level. This interest has also led him to a position as adjunct professor in the Marshall School of Business at the University of Southern California. Before his tenure at Zone Ventures, Dr. Sankey worked as a management consultant at McKinsey & Company, Inc. and held strategic planning, consulting, and R&D positions at RAND and AT&T Bell Laboratories. Dr. Sankey holds a B.S. in Physics and Electrical Engineering from MIT and a Ph.D. in Optical Engineering from the Institute of Optics, University of Rochester.
Currently Dr. Sankey teaches "Lab to Market" class at Rady School of Management (UCSD) as a visiting professor.
2. SABPA New Year Party (01/24/09)
The Saturday night of 24th SABPA committee members, friends, and family members gathered at the Valley Club of Carlsbad to celebrate Chinese New Year, and another successful year of the organization. Set from the very beginning the mission of SABPA to create values to our members and community, SABPA enjoyed a steady growth in 2008 by fully utilizing the strengths and motivation of leadership teams and volunteers as well.
The smooth and effective transfer of leadership roles from Dr. Hui Li to Dr. Xiangming Fang (San Diego Chapter) and from Dr. Ying Zhao to Dr. Hengchu Cao (OC/LA Chapter) was well received. We appreciated dedicated contributions in the past two years Drs Hui Li and Ying Zhao had devoted as Chapter President that collectively brought SABPA to what we are today. Going forward, we believe our new leaders will have strong supports from all of our members as well.
3. SABPA 2008 Awards
2008 SABPA Awards, including Achievement, Leadership, and Team Awards, were presented at SABPA New Year party, with the applauding for recognizing the excellences and with showing great respects to those outstanding contributors. The awardees also shared the collaborative and generous spirits that they experienced at every SABPA event. Not surprisingly, those characteristics are strengths that have allowed SABPA to develop and flourish steadily and productively.
Leadership Award: Hui Li.
Achievements Award: Daniel Gong, Yahu Liu, Shuyan Liu, Wenshuo Lu, Yinong Xie, Mai Zhang, Peter Zhu.
Team Award: Jia Liu & Tia Chen.
4. SABPA Science & Technology Forum VII (San Diego Chapter, 03/21/09)
Biomarker, Pharmacogenomics and Personalized Medicine
Date: March 21, 2009 (Saturday)
Location: Institute of Americas, UCSD (directions available at www.sabpa.org)
Pharmaceuticals industry has been operating under the paradigm of "one drug fits all" for many decades. However, many drugs are often ineffective in many of the patients, and could even cause serious adverse effects in certain patient populations. These obstacles, in addition to tougher FDA review and rapidly evaporating pipeline, have put unprecedented challenges to the drug developers, and will inevitably push the industry to make a paradigm shift towards "right drug to right patient", so called personalized medicine. The topic of SABPA Science & Technology Forum VII will focus on recent advances in the development of biomarkers and pharmacogenomics to realize the promise of personalized medicine. Experts from both academia and industry will present overview as well as specific examples of using rapid advance in high density microarray technology, genome-wide RNA expression profiling and DNA genotyping to identify novel genomic biomarkers, and to predict drug efficacy and adverse effects. These approaches are poised to dramatically shorten the development cycle, increase the efficacy and safety of new drugs, and ultimately deliver the right medicine tailored to the right patients.
Confirmed speakers & presentations
Nicholas J. Schork, Ph.D.
Director of Research, Scripps Genomic Medicine, Director of Biostatistics and Bioinformatics, The Scripps Translational Science Institute
Genetic Variation, Association Studies, and Personalized Medicine
Yixin Wang, Ph.D.
Executive Director, Research & Development, Veridex, LLC., a Johnson & Johnson Company
Molecular Profiling of Cancer: Research Tools or Novel Clinical Diagnostics?
Dominic Spinella, Ph.D.
Executive Director, Translational and Molecular Medicine, Pfizer Biotechnology and Bioinnovation Center (BBC)
Personalized Medicine: Practical Considerations for Drug Development
Wen Luo, Ph.D.
Research Investigator, New Leads Discovery, Ligand Pharmaceuticals, San Diego
Applying genomic biomarkers to predict drug response: Rescue a phase III cancer drug with a genome-wide pharmacogenomic study
Dominic Eisinger, Ph.D.
Director, Strategic Development , Rules Based Medicine
Disease Related Protein Biomarker Profiles: Successful Strategies And Applications In Drug Development And Diagnostics
5. SABPA 4th Biomedical Forum (OC/LA Chapter, 03/28/09)
This is a premier annual technology and business conference for entrepreneurs, scientists, industry executives, investors and policy makers in the medical device industry in Southern California and Pacific Asia. You are cordially invited to join our members and sponsors to enjoy the event. For more information about SABPA and the conference, please visit http://www.sabpa.org.
The main topics for this year's event will be how to create, innovate, and sustain health care companies in the current global economic environment and continue to transform product ideas into profitable companies and business.
Market leaders and newly formed companies in the US, China and Southern California regions will present
• Latest innovations in medical devices and biotechnology/pharmaceutical in US & China
• How to turn product ideas into profits – Product Inception, Development, Funding and Commercialization
• How to find funding for each stage of development
• Commercial opportunities in US & China
Core Program and Distinguished Speakers include:
The BOTOX® story
Mitchell Brin, MD, Senior Vice President, Global Drug Development & Chief Scientific Officer, Allergan, LLC. & Clinical Professor of Neurology, University of California, Irvine
Principals and Practices in Medical Device Innovation
Stan Rowe, Chief Scientific Officer, Corporate Vice President, Advanced Technology, Edwards Lifesciences, LLC
Pharmaceutical osteogenic potentials in osteoporosis and fracture healing – Transform basic research into clinical practice
David Ke, M.D., Executive Scientific Director, Amgen, Inc.
Trends in Cardiac Rhythm Management and Neuromodulation devices
Peter Chen, Ph.D. President, Center for Innovation and Strategic Collaboration, St. Jude Medical, Inc.
Investment Criteria in the New Global Economy
Daren Chen, Hillcrest Venture Partners, A New Lifescience Venture Fund.
6. Genengnews Report on 4th SABPA Pacific Forum (11/08/08)
Cautious Optimism Prevails for Chinese Biotechnology
Government's Commitment and Return of "Sea Turtles" Buoy the Industry
The Chinese word for "crisis" is composed of two characters—one for danger and one for opportunity. That analogy sums up, not only the current global situation, but the situation for biotechs in China too, according to speakers at the recent "Pacific Forum on Life Science Alliances," sponsored by the Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA). Read the full story
http://www.genengnews.com/articles/chitem.aspx?aid=2715
7. Community Events
1). IBC's 3rd International Conference
ACCESS India & China
February 9-10, 2009
Sheraton Hotel & Marina, in San Diego, California
www.IBCLifeSciences.com/ACCESS
IBC Life Sciences announces that the ACCESS India & China international conference will take place at the Sheraton Hotel & Marina, in San Diego, California on February 9-10, 2009.
As the Asia partnering landscape is rapidly changing, IBC Life Sciences' ACCESS India & China helps to uncover not just the capabilities of Asian partners, but also any potential gaps in preclinical sourcing and inventory resources, along with techniques to overcome them. Formerly titled "Biology, Preclinical and Beyond in India and China", this year's conference focuses on examples of partnerships where companies were able to combine resources, increase capacity, gain speed and find new ideas.
Key Themes include:
• Leveraging Integrated Biology and Chemistry Services in China and India to Speed up Drug Discovery and Development
• Scientific and Technological Innovations to Alleviate Bottlenecks in the R&D Pipeline
• Growing Capabilities of Academic Research Centers and Successfully Tapping Lucrative Therapeutic Area Research
• Unraveling Regulatory Challenges and Protecting Intellectual Property in Asia to Enable Solid Infrastructure Growth
Also featured are two panel sessions, The CRO Renaissance and Bridging East and West: Licensing & Partnering Trends across the Pacific. Both will facilitate discussion on the expansion and recent changes of the pharmaceutical marketplace in China and India and how this impacts multinational pharmaceutical and biotech companies.
For up-to-date information and to register for this event, visit www.IBCLifeSciences.com/ACCESS.
2). China 2009 Pharmaceutical R & D Summit
SABPA members get 20% off the Full Conference Rate. Use Priority Code: IR9163SABPAE
As a SABPA member, you are invited to join us at the China 2009 Pharmaceutical R&D Summit, April 7-9, 2009 in Shanghai, China. Attend to quickly get up-to-speed on the current scientific advances in China and gain insights into how to grow and maximize your presence in China's burgeoning life sciences industry.
Find Out What it Takes to Sustain & Maximize Your Competitive Advantage in China's Life Sciences Industry
This conference will bring together global and local luminaries to discuss China's role in the global pharmaceutical landscape, the challenging environment that pharmaceutical companies in the world will face in the coming months or years; the dearth of innovation and where China can play a role in innovative discovery; the ever increasing importance of clinical trials in China as well as the expanding focus
Want to learn more? Visit www.IBCLifeSciences.com/China
3). UCLA Anderson School of Management Greater China Business Conference
February 27, 2009, UCLA Anderson School of Management, Korn Hall
The Wilbur K. Woo Greater China Business Conference at the UCLA Anderson School of Management aims to bring business leaders, professionals, academics, and MBA students together to discuss business trends, challenges, and impacts of the increasing role of Greater China in the global economy, including topics on investment, partnering, innovation, life science, clean tech, building brands. Speakers include Zhu Shen | Chief Executive Officer of BioForesight & SABPA Vice Chairman, Michael Gisser | Partner at Skadden, Arps, Slate, Meagher & Flom LLP, James Zukin | Chairman of Asia and Senior Managing Director at Houlihan Lokey, Cheng Si-Wei | Vice Chairman Standing Committee of the National People's Congress, Jane Gannaway | Engineering at Yum! China and others. UCLA Anderson School's Dean and John E. Anderson Chair in Management, Judy D. Olian will give opening remarks. About 280 attendees were present at the 2008 conference, over 200 attendees are expected for 2009.
Conference agenda: http://www.anderson.ucla.edu/x21283.xml
The Panels and Networking Reception still have sponsorship opportunities available. For more details or registration visit www.anderson.ucla.edu. Use code "SABPA" for $20 off general admission.
8. Job Openings
Toshiba Medical Research Institute USA, Inc.
706 N. Deerpath Drive
Vernon Hills, IL 60061
1. Senior Scientist, Immunoassay Development
Qualifications:
PhD in immunochemistry or immunology plus postdoctoral and industrial experience
Responsibilities:
Lead immunoassay development in support of system and instrument development, assessment of technologies for acquisitions, evaluation of competing technologies, assist in patent evaluation and support business development.
Experience:
10-15 years experience in immunoassay development, binding studies, purification and labeling (conjugation) of antibodies, thorough knowledge of homogeneous immunoassays, record of achievement in vitro diagnostics by patents and publications.
2. In vitro Diagnostics Immunochemist
Qualifications:
PhD in immunochemistry, biochemistry or immunology plus postdoctoral and industrial experience
Responsibilities:
Participate in research and support of system and instrument development
Experience:
Five years experience in immunoassay development, binding studies, purifications and labeling (conjugation) of antibodies, thorough knowledge of homogeneous and heterogeneous immunoassays
3. Senior Scientist Molecular Diagnostics
Qualifications:
PhD in molecular biology, nucleic acid chemistry, immunochemistry or biochemistry plus postdoctoral and industry experience
Responsibilities:
Lead molecular diagnostics development team in support of system and instrument development, assessment of technologies for acquisitions, assist in evaluation of competing technologies, assist in patent evaluations and support business development.
Experience:
10-15 years experience in nucleic acid assay development including sample preparations, binding studies, purification and labeling (conjugation) of antibodies, thorough knowledge of homogeneous assays, achievement in molecular diagnostics as evidenced by patents and publications are requires.
Abbott R&D Center, Shanghai
Company: Abbott has established an R&D center in Shanghai to provide biology support for lead discovery and optimization programs in CNS, cancer, immunology, and viral disease therapeutic areas. We are looking for an experienced scientist to join us and help build the R&D center into a state-of-the-art facility for drug discovery and development.
Position: Senior Scientist/Principal Scientist/Group Leader
Responsibilities:
• Assist site head in scientific and management activities in the R&D center, including project planning, project management, recruiting, staff training, and lab management
• Play active role in helping to establish Abbott corporate culture and collaborating with other GPRD sites on research projects
• Lead a team of scientists to support drug discovery projects in multiple therapeutic disease areas with focus on in vitro and cell biology
• Provide hands-on support as needed and supervise staff to carry out drug discovery activities on target cloning/characterization, reagent generation, assay development, hit-to-lead, MOA studies, and other lead optimization support
• Play active role in communicating with other R&D sites on project management and update
• Participate in management of contract research activities
• Participate in external collaborations
Requirements:
• Minimum requirement is Ph.D. or equivalent in biology or related disciplines with 3+ years of experience in pharmaceutical or biotech industries, or MS with 10+ years of experience
• Excellent English, communication, and presentation skills
• Experience in project leadership preferred but not required
• Hands-on experience in assay development, compound profiling, and mechanism of action studies
• Expertise in kinases, GPCRs, cell-based assays, and enzyme assays preferred
• Familiar with various in vitro and cell-based assay formats and detection methods
• Familiar with data processing and other scientific software
• Responsible, attention to details, organized
Location: The Abbott R&D center is located in Zhangjiang Hi-Tech Park East Area, Pudong New District, Shanghai. Relocation to Shanghai is required for this position.
Contact: Please contact Dr. Bin Li at Dr.Binli@abbott.com or binli1@yahoo.com for more details and to apply for the position.
|
|
 |
|
 |
|
|
